AR052580A1 - Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias - Google Patents
Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- AR052580A1 AR052580A1 ARP060100701A ARP060100701A AR052580A1 AR 052580 A1 AR052580 A1 AR 052580A1 AR P060100701 A ARP060100701 A AR P060100701A AR P060100701 A ARP060100701 A AR P060100701A AR 052580 A1 AR052580 A1 AR 052580A1
- Authority
- AR
- Argentina
- Prior art keywords
- monocyclic
- group
- bicyclic
- aromatic
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Reivindicacion No. 1:Un compuesto caracterizado porque está representado por la siguiente formula estructural (1) o una sal farmacéuticamente aceptable del mismo, donde : El anillo A es un anillo arilo o heteroarilo, de 5-6 miembros, condensado, opcionalmente sustituido; Y es >C(Rx)- o >N-; X1 es -C(=O)-, -SO2-, -CONR-, -C«2- o -CO2-, R1 es un grupo opcionalmente sustituido seleccionado entre un grupo alifático, un arilo monocíclico o bicíclico, un heteroarilo monocíclico o bicíclico, un heterociclilo monocíclico o bicíclico no aromático o un grupo carbociclilo monocíclico o bicíclico no aromático; R2 es un grupo alquilo C1-3, un grupo haloalquilo C1-3 o un grupo cicloalquilo C3-6, o un grupo opcionalmente sustituido seleccionado entre un grupo cicloalquilo C3-8, un grupo heterocíclico monocíclico no aromático, un arilo monocíclico o un grupo heteroarilo monocíclico; R4 es -[C(R7)2]m-B; o R3 y R4 se forman junto con el átomo de nitrogeno situado entre ellos para formar un grupo heteroarilo monocíclico o bicíclico, opcionalmente sustituido o un grupo heterocíclico no aromático; o Rx y R4 se toman junto con los átomos de carbono y nitrogeno situados entre ellos para formar un grupo heterocíclico que contiene nitrogeno, no aromático, monocíclico, opcionalmente sustituido; R5 es -OH, -O(grupo alifático C1-4)-COOR' o -N(R')2; R6 es -OH, -O(grupo alifático C1-4), N(R')2, -C(O)R', -COOR', C(O)N(R')2 o un grupo opcionalmente sustituido seleccionado ente un cicloalquilo monocíclico, un arilo monocíclico, un heteroarilo monocíclico o un grupo heterocíclico no aromático monocíclico; cada R7 es independientemente hidrogeno o un grupo alifático C1-4 o N(R')2 es un grupo heterocíclico que contiene nitrogeno, no aromático, monocíclico; m es cero o uno; y B es -H, -C(R7)3, -C(R7)3-C(R7)3 o un grupo opcionalmente sustituido seleccionado ente un cicloalquilo monocíclico o bicíclico, un arilo monocíclico o bicíclico, un heteroarilo monocíclico o bicíclico o un grupo heterocíclico no aromático, monocíclico o bicíclico, con la condicion de que los compuestos de formula(1) sean distintos de los compuestos en los que X1 es -COO- y R1 es etilo y el anillo A está sustituido con: a) dos apariciones de OMe, a) dos apariciones de Me, o c) una aparicion de CF3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65592705P | 2005-02-24 | 2005-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052580A1 true AR052580A1 (es) | 2007-03-21 |
Family
ID=36593677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100701A AR052580A1 (es) | 2005-02-24 | 2006-02-24 | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias |
Country Status (26)
Country | Link |
---|---|
US (1) | US7951950B2 (es) |
EP (1) | EP1861372A1 (es) |
JP (1) | JP2008543726A (es) |
KR (1) | KR20070114762A (es) |
CN (1) | CN101146776A (es) |
AR (1) | AR052580A1 (es) |
AU (1) | AU2006216713A1 (es) |
BR (1) | BRPI0608553A2 (es) |
CA (1) | CA2598133A1 (es) |
CR (1) | CR9378A (es) |
DO (1) | DOP2006000054A (es) |
GT (1) | GT200600093A (es) |
IL (1) | IL185422A0 (es) |
MA (1) | MA29330B1 (es) |
MX (1) | MX2007010215A (es) |
NI (1) | NI200700221A (es) |
NO (1) | NO20074388L (es) |
PE (1) | PE20061013A1 (es) |
RU (1) | RU2007135224A (es) |
SV (1) | SV2007002429A (es) |
TN (1) | TNSN07325A1 (es) |
TW (1) | TW200640869A (es) |
UA (1) | UA90706C2 (es) |
UY (1) | UY29397A1 (es) |
WO (1) | WO2006091674A1 (es) |
ZA (1) | ZA200707498B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITVA20050050A1 (it) * | 2005-08-05 | 2007-02-06 | Lamberti Spa | Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita' |
US20100015085A1 (en) * | 2006-05-01 | 2010-01-21 | Johns Hopkins University | Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress |
AU2008337342B2 (en) | 2007-12-14 | 2012-05-24 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
CA2730390A1 (en) | 2008-07-15 | 2010-01-21 | F.Hoffmann-La Roche Ag | Aminotetrahydroindazoloacetic acids |
EP2307382B1 (en) | 2008-07-15 | 2011-12-21 | F. Hoffmann-La Roche AG | Aminotetrahydroindazoloacetic acids |
CA2734104A1 (en) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Substituted aminotetralines |
CN102149677A (zh) | 2008-08-15 | 2011-08-10 | 霍夫曼-拉罗奇有限公司 | 联芳基氨基四氢化萘类 |
SG171734A1 (en) | 2008-11-17 | 2011-07-28 | Hoffmann La Roche | Naphthylacetic acids |
WO2010055005A1 (en) | 2008-11-17 | 2010-05-20 | F. Hoffmann-La Roche Ag | Naphthylacetic acids |
JP5373104B2 (ja) * | 2008-11-17 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | Crth2アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸 |
CN102958914B (zh) | 2010-07-05 | 2015-05-27 | 埃科特莱茵药品有限公司 | 1-苯基取代的杂环衍生物及其作为***素d2受体调节剂的用途 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
AU2012271661B8 (en) * | 2011-06-17 | 2016-11-10 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
US8470884B2 (en) | 2011-11-09 | 2013-06-25 | Hoffmann-La Roche Inc. | Alkenyl naphthylacetic acids |
US8691993B2 (en) * | 2011-12-12 | 2014-04-08 | Hoffmann-La Roche Inc. | Piperidinyl naphthylacetic acids |
JP2015500326A (ja) | 2011-12-16 | 2015-01-05 | アトピックス テラピューティクス リミテッド | 好酸球性食道炎の治療のためのcrth2拮抗薬およびプロトンポンプ阻害薬の組み合わせ |
EP2794563B1 (en) | 2011-12-21 | 2017-02-22 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
US9296723B2 (en) * | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
TW201350478A (zh) * | 2012-05-11 | 2013-12-16 | Abbvie Inc | Nampt抑制劑 |
CN104271572A (zh) * | 2012-05-11 | 2015-01-07 | 艾伯维公司 | 用作nampt抑制剂的噻唑羧酰胺衍生物 |
WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
RS61519B1 (sr) | 2013-11-18 | 2021-03-31 | Forma Therapeutics Inc | Sastavi tetrahidrohinolina kao inhibitori bet bromodomena |
US9727784B2 (en) * | 2014-06-03 | 2017-08-08 | Digitalglobe, Inc. | Some automated and semi-automated tools for linear feature extraction in two and three dimensions |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2089033T3 (es) | 1989-10-20 | 1996-10-01 | Otsuka Pharma Co Ltd | Compuestos benzoheterociclicos. |
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
AU657424B2 (en) | 1992-07-02 | 1995-03-09 | Otsuka Pharmaceutical Co., Ltd. | Oxytocin antagonist |
MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
EP1100495A4 (en) | 1998-07-28 | 2002-09-25 | Smithkline Beecham Corp | PROPENAMIDES AS CCR5 MODULATORS |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6048873A (en) * | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
WO2001027086A1 (fr) | 1999-10-14 | 2001-04-19 | Kaken Pharmaceutical Co., Ltd. | Derives de tetrahydroquinoline |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
MXPA02006617A (es) | 2000-01-03 | 2004-09-10 | Pharmacia Corp | Dihidrobenzopiranos, dihidrobenzotiopiranos, y tetrahidroquinolinas para el tratamiento de desordenes mediados por cox-2. |
DE10005302A1 (de) | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
EP1283055A4 (en) | 2000-04-07 | 2003-05-07 | Takeda Chemical Industries Ltd | SOLUBLE SECRETION PROMOTERS OF THE BETA-AMYOID PROTEIN PRECURSOR |
US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
JP2002053557A (ja) | 2000-08-14 | 2002-02-19 | Japan Tobacco Inc | アポリポ蛋白a−i産生促進薬 |
DE60116642T2 (de) | 2000-08-29 | 2006-11-09 | Allergan, Inc., Irvine | Verbindungen mit cytochrom p450ra1 hemmenden aktivität |
US6291677B1 (en) * | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6313107B1 (en) * | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
WO2002022585A1 (fr) | 2000-09-14 | 2002-03-21 | Kaken Pharmaceutical Co., Ltd. | Composes de tetrahydroquinoline |
DE10103657A1 (de) | 2001-01-27 | 2002-08-01 | Henkel Kgaa | Neue Kupplerkomponente für Oxidationsmittel |
SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
CN1297541C (zh) * | 2001-04-30 | 2007-01-31 | 辉瑞产品公司 | 制备胆固醇酯转运蛋白抑制剂的方法 |
EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
JP2006508077A (ja) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのpgd2レセプタアンタゴニスト |
US7504508B2 (en) * | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
BR0315547A (pt) | 2002-10-21 | 2005-09-20 | Warner Lambert Co | Derivados de quinolina como antagonistas de crth2 |
EP1413306A1 (en) | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
JPWO2004052863A1 (ja) | 2002-12-06 | 2006-04-13 | 協和醗酵工業株式会社 | 抗炎症剤 |
EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
JP2006521344A (ja) * | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症および肥満の治療のためのcetp阻害剤としての1,2,4−置換1,2,3,4−テトラヒドロ−および1,2−ジヒドロ−キノリンおよび1,2,3,4−テトラヒドロ−キノキサリン誘導体 |
WO2005007094A2 (en) * | 2003-07-09 | 2005-01-27 | Tularik Inc. | Asthma and allergic inflammation modulators |
BRPI0509668A (pt) | 2004-04-07 | 2007-10-09 | Millennium Pharm Inc | composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto |
-
2006
- 2006-02-23 CA CA002598133A patent/CA2598133A1/en not_active Abandoned
- 2006-02-23 EP EP06735798A patent/EP1861372A1/en not_active Withdrawn
- 2006-02-23 CN CNA2006800096718A patent/CN101146776A/zh active Pending
- 2006-02-23 MX MX2007010215A patent/MX2007010215A/es not_active Application Discontinuation
- 2006-02-23 KR KR1020077021757A patent/KR20070114762A/ko not_active Application Discontinuation
- 2006-02-23 UA UAA200710441A patent/UA90706C2/ru unknown
- 2006-02-23 RU RU2007135224/04A patent/RU2007135224A/ru not_active Application Discontinuation
- 2006-02-23 JP JP2007557128A patent/JP2008543726A/ja active Pending
- 2006-02-23 WO PCT/US2006/006287 patent/WO2006091674A1/en active Application Filing
- 2006-02-23 BR BRPI0608553-9A patent/BRPI0608553A2/pt not_active IP Right Cessation
- 2006-02-23 ZA ZA200707498A patent/ZA200707498B/xx unknown
- 2006-02-23 GT GT200600093A patent/GT200600093A/es unknown
- 2006-02-23 AU AU2006216713A patent/AU2006216713A1/en not_active Withdrawn
- 2006-02-23 US US11/360,885 patent/US7951950B2/en active Active
- 2006-02-24 DO DO2006000054A patent/DOP2006000054A/es unknown
- 2006-02-24 UY UY29397A patent/UY29397A1/es not_active Application Discontinuation
- 2006-02-24 TW TW095106336A patent/TW200640869A/zh unknown
- 2006-02-24 SV SV2006002429A patent/SV2007002429A/es unknown
- 2006-02-24 PE PE2006000220A patent/PE20061013A1/es not_active Application Discontinuation
- 2006-02-24 AR ARP060100701A patent/AR052580A1/es unknown
-
2007
- 2007-08-21 IL IL185422A patent/IL185422A0/en unknown
- 2007-08-23 NI NI200700221A patent/NI200700221A/es unknown
- 2007-08-24 TN TNP2007000325A patent/TNSN07325A1/en unknown
- 2007-08-29 NO NO20074388A patent/NO20074388L/no not_active Application Discontinuation
- 2007-09-11 MA MA30215A patent/MA29330B1/fr unknown
- 2007-09-12 CR CR9378A patent/CR9378A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UA90706C2 (ru) | 2010-05-25 |
WO2006091674A1 (en) | 2006-08-31 |
NI200700221A (es) | 2008-05-09 |
PE20061013A1 (es) | 2006-10-13 |
UY29397A1 (es) | 2006-10-02 |
TW200640869A (en) | 2006-12-01 |
US20060241109A1 (en) | 2006-10-26 |
CN101146776A (zh) | 2008-03-19 |
RU2007135224A (ru) | 2009-03-27 |
SV2007002429A (es) | 2007-02-19 |
CR9378A (es) | 2008-01-21 |
AU2006216713A1 (en) | 2006-08-31 |
CA2598133A1 (en) | 2006-08-31 |
MX2007010215A (es) | 2007-11-07 |
GT200600093A (es) | 2006-10-19 |
JP2008543726A (ja) | 2008-12-04 |
KR20070114762A (ko) | 2007-12-04 |
BRPI0608553A2 (pt) | 2010-01-12 |
NO20074388L (no) | 2007-11-20 |
IL185422A0 (en) | 2008-01-06 |
EP1861372A1 (en) | 2007-12-05 |
ZA200707498B (en) | 2008-11-26 |
TNSN07325A1 (en) | 2008-12-31 |
DOP2006000054A (es) | 2006-08-31 |
MA29330B1 (fr) | 2008-03-03 |
US7951950B2 (en) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052580A1 (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
BR112020008851A2 (pt) | composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas | |
MX2020010682A (es) | Conjugado de anticuerpo-farmaco anti-receptor 2 del factor de crecimiento epidermal (her2). | |
AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
EA201171328A1 (ru) | Производное замещенного изохинолина | |
AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
ECSP066760A (es) | Derivado de 4-oxopirimidina de anillos condensados | |
GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
MD20150019A2 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile | |
MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
MX2021006404A (es) | Derivados de piridona policiclica sustituida y profarmaco de los mismos. | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
MY163164A (en) | Ethynyl derivatives as positive allosteric modulators of the mglur5 | |
PH12015502751A1 (en) | Preparation of tert-butyl 4-((1r,2s,5r)-6- (benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.i]octane-2- carboxamido)piperidine-1-carboxylate | |
EA201001087A1 (ru) | Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
CO6341560A2 (es) | Proceso para la preparacion de derivados de pirimidina sustituidos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |